Immuron to Participate in H.C. Wainwright & Co. BioConnect 2021 Virtual Conference
January 11, 2021 06:00 ET
|
Immuron Limited
MELBOURNE, Australia, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercialising oral...
Immuron SARS-CoV-2 Research Agreement with Monash University
December 15, 2020 06:00 ET
|
Immuron Limited
Key Points Immuron’s Hyper-immune Bovine Colostrum, used to manufacture Travelan® and Protectyn®, demonstrated antiviral activity against the SARS-CoV-2/COVID-19 virus in laboratory studies.A New...
Immuron Receives AUD $358,280 R&D Tax Concession Refund
November 24, 2020 06:00 ET
|
Immuron Limited
MELBOURNE, Australia, Nov. 24, 2020 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral...
US DoD Naval Medical Research Center Reports Positive Immunological Responses to Vaccine
November 11, 2020 06:00 ET
|
Immuron Limited
Key Points NMRC demonstrated functional antibodies in new oral therapeutic targeting Campylobacter and ETECImmuron executes a Research Agreement with PCI Clinical Services to manufacture drug...
Fluidigm to Present at Upcoming Health Care Investor Conference
November 10, 2020 08:30 ET
|
Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive...
Innovation Metals Corp. Announces RapidSX™ Commercialization and Development Facility; Kingston Process Metallurgy Awarded Contract as RapidSX™ Laboratory Partner
June 23, 2020 14:08 ET
|
Innovation Metals Corp.
TORONTO, June 23, 2020 (GLOBE NEWSWIRE) -- Innovation Metals Corp. (“IMC” or the “Company”) is pleased to announce that the Company has executed a binding agreement with Kingston Process Metallurgy...
Immuron Partners with CSIRO to produce a new oral therapeutic for clinical evaluation by the US Department of Defense
June 19, 2020 06:00 ET
|
Immuron Limited
Key Points Immuron executes a Research Agreement with The Henry M. Jackson Foundation for Advancement of Military Medicine Inc.Immuron executes a Research Agreement with CSIRO to develop a new oral...
US DoD Naval Medical Research Center Requests Meeting with FDA for Guidance on two Phase 2 trials to Prevent Acute Infectious Diarrhea
June 09, 2020 06:00 ET
|
Immuron Limited
Key Points NMRC requests Pre-IND meeting with FDA on the development of a new oral therapeutic targeting Campylobacter and ETEC Two human phase II clinical trials to be conducted in 2021One trial...
Ucore Rare Metals to Acquire Innovation Metals Corp. and RapidSX™ Separation Technology
April 29, 2020 10:16 ET
|
Innovation Metals Corp.
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION OR DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES ...
Immuron Board Relinquish Cash Payment of Fees
April 28, 2020 06:00 ET
|
Immuron Limited
MELBOURNE, Australia, April 28, 2020 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral...